DBV Technologies (NASDAQ:DBVT) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Friday. The firm presently has a $26.00 target price on the stock. Zacks Investment Research‘s price objective suggests a potential upside of 18.10% from the company’s previous close.
According to Zacks, “DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France. “
Other equities research analysts have also issued reports about the stock. Citigroup set a $57.00 target price on shares of DBV Technologies and gave the stock a “buy” rating in a research report on Wednesday, February 14th. BidaskClub upgraded shares of DBV Technologies from a “sell” rating to a “hold” rating in a research report on Friday, December 29th. Finally, HC Wainwright restated a “buy” rating on shares of DBV Technologies in a research report on Thursday, March 15th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $48.88.
Several hedge funds and other institutional investors have recently modified their holdings of DBVT. Quantbot Technologies LP purchased a new stake in shares of DBV Technologies during the 3rd quarter worth $146,000. Commonwealth Equity Services Inc acquired a new position in shares of DBV Technologies during the 3rd quarter worth $233,000. Dynamic Technology Lab Private Ltd raised its stake in shares of DBV Technologies by 87.6% during the 3rd quarter. Dynamic Technology Lab Private Ltd now owns 11,655 shares of the company’s stock worth $495,000 after buying an additional 5,441 shares during the last quarter. Citadel Advisors LLC acquired a new position in shares of DBV Technologies during the 3rd quarter worth $7,794,000. Finally, Granite Point Capital Management L.P. acquired a new position in shares of DBV Technologies during the 3rd quarter worth $1,698,000. Institutional investors own 45.68% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This story was originally posted by Ticker Report and is owned by of Ticker Report. If you are accessing this story on another site, it was stolen and republished in violation of U.S. & international copyright legislation. The legal version of this story can be read at https://www.tickerreport.com/banking-finance/3294198/dbv-technologies-dbvt-upgraded-at-zacks-investment-research.html.
DBV Technologies Company Profile
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.